anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A biologically active substance in a form of ethanol extract from castoreum is prepared by the method comprising the preparation of raw material, the drying of the prepared raw material, the steam treatment, the mincing of the dried raw material, the extraction of the dried raw material, the conditioning and the settling of the extract. The raw material is dried in two steps. The first step comprises the gradual increase of the temperature from 30° to 100- until the water content of 50 %. The second step follows the stage of the mincing. The steam treatment is provided under the pressure below 2 atm. for 1-10 min. The raw material : extractant ratio is from 0.5:10 to 5:30 with 40-70 % ethanol as an extractant. The conditioning includes the periodical mixing of extractable mixture. The extract is settled until the brown coloration of supernatant.
A computer system with a workflow server that provides for automatic and prioritized assignment of work involving processing of medical information records (202) to particular resources in a hospital. When medical records are no longer needed, it may be written by the file server on to optical disk (230). A page table (28) may also receive data on medical records (202) via MIS  integration block (290). Documents are accessed via the file server at coding/abstracting workstation (214) or via work-station (216). A  plurality of such workstations may be attached to the file server to perform chart coding/abstracting and chart deficiency completion. Documents may also be accessed at print station (218) and printed on printer (260).
Strokes cause spasticity via stretch reflex hyperexcitability in the spinal cord, and spastic paralysis due to involuntary muscle contraction in the hands and fingers can severely restrict skilled hand movements. However, the underlying neurological mechanisms remain unknown. Using a mouse model of spasticity after stroke, we demonstrate changes in neuronal activity with and without electrostimulation of the afferent nerve to induce the stretch reflex, measured using quantitative activation-induced manganese-enhanced magnetic resonance imaging. Neuronal activity increased within the ventral medullary reticular formation (MdV) in the contralesional brainstem during the acute post-stroke phase, and this increase was characterised by activation of circuits involved in spasticity. Interestingly, ascending electrostimulation inhibited the MdV activity on the stimulation side in normal conditions. Moreover, immunohistochemical staining showed that, in the acute phase, the density of GluA1, one of the α-amino-3 hydroxy‑5 methyl -4 isoxazolepropionic acid receptor (AMPAR) subunits, at the synapses of MdV neurons was significantly increased. In addition, the GluA1/GluA2 ratio in these receptors was altered at 2 weeks post-stroke, confirming homeostatic plasticity as the underlying mechanisms of spasticity. These results provide new insights into the relationship between impaired skilled movements and spasticity at the acute post-stroke phase.
BACKGROUND: The implantation of left ventricular assist devices (LVADs) as a bridge to transplantation or as destination therapy in end-stage heart failure patients is frequently complicated by the emergence of ventricular arrhythmias (VAs). These arrhythmias have been implicated in precipitating deleterious clinical outcomes, increased mortality rates and augmented healthcare expenditures.
CASE PRESENTATION: We present a challenging case of a 49-year-old male with a history of dilated cardiomyopathy who received an LVAD. Post-implantation, the patient suffered from intractable VAs, leading to multiple rehospitalizations and hemodynamic deterioration. Despite exhaustive medical management and electrical cardioversion attempts, the patient's VAs persisted, ultimately necessitating prioritization for cardiac transplantation.
DISCUSSION: This case highlights the challenges in managing VAs in LVAD patients and the importance of multidisciplinary collaboration. While pharmacological intervention is the initial strategy, catheter ablation may be considered in selected cases when medication is insufficient. In instances of intractable VAs, expeditious listing for heart transplantation as a high-priority candidate is advisable when feasible.
BACKGROUND AND PURPOSE: To protect against SARS-CoV-2 infection, the first mRNA-based vaccines, Spikevax (mRNA-1273, Moderna) and Comirnaty (BNT162b2, Pfizer/Biontech), were approved in 2020. The structure and assembly of the immunogen-in both cases, the SARS-CoV-2 spike (S) glycoprotein-are determined by a messenger RNA sequence that is translated by endogenous ribosomes. Cardiac side-effects, which for the most part can be classified by their clinical symptoms as myo- and/or pericarditis, can be caused by both mRNA-1273 and BNT162b2.
EXPERIMENTAL APPROACH: As persuasive theories for the underlying pathomechanisms have yet to be developed, this study investigated the effect of mRNA-1273 and BNT162b2 on the function, structure, and viability of isolated adult rat cardiomyocytes over a 72 h period.
KEY RESULTS: In the first 24 h after application, both mRNA-1273 and BNT162b2 caused neither functional disturbances nor morphological abnormalities. After 48 h, expression of the encoded spike protein was detected in ventricular cardiomyocytes for both mRNAs. At this point in time, mRNA-1273 induced arrhythmic as well as completely irregular contractions associated with irregular as well as localized calcium transients, which provide indications of significant dysfunction of the cardiac ryanodine receptor (RyR2). In contrast, BNT162b2 increased cardiomyocyte contraction via significantly increased protein kinase A (PKA) activity at the cellular level.
CONCLUSION AND IMPLICATIONS: Here, we demonstrated for the first time, that in isolated cardiomyocytes, both mRNA-1273 and BNT162b2 induce specific dysfunctions that correlate pathophysiologically to cardiomyopathy. Both RyR2 impairment and sustained PKA activation may significantly increase the risk of acute cardiac events.
Objective This study examined the prevalence of migraine in nurses in Japan, which, to our knowledge, has not been documented in English. Methods From April to May 2021, we administered a questionnaire to 229 nurses working at Keio University Hospital to investigate the prevalence and characteristics of headache among nurses in Japan. Headaches were classified as migraine or tension-type headache (TTH) based on the International Classification of Headache Disorders 3rd edition (ICHD-3). Results In total, 80 patients (34.9%) had primary headaches, including 47 (20.5%) with migraine and probable migraine and 33 (14.4%) with TTH and probable TTH. We found a significant difference in the Numerical Rating Scale score, nausea and vomiting, photophobia, phonophobia, and aggravation by routine physical activity between migraine and TTH. The specificities for a migraine diagnosis were 100% and 93.9% for nausea/vomiting and photophobia, respectively. Only 8.8% of patients had their headaches diagnosed by a physician. Conclusion Migraines have a high prevalence (>20%) among nurses and are often under-diagnosed. In many cases, headache-associated symptoms are more important than laterality or other characteristics for the diagnosis. Many nurses are treated for headaches without a correct diagnosis. Further education regarding primary headaches may be necessary for health practitioners as well as society.
The invention is related to methods for culturing stem cells, more particularly hematopoietic stem cells (HSC). The invention relates to methods for HSC expansion and the use of factors to increase the retention and/or expansion of KLS cells in vitro. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of disorders or diseases (e.g. leukemia). The invention also relates to the development of small molecules that may increase HSC self renewal in vitro and in vivo.
Participants in the experimental group were given 150,000 IU (10 ml) of vitamin D3 supplementation, and it was used regularly for 2 months. From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 measurements were taken from the participants.
A concomitant therapy consisting of Hydroxychloroquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Hydroxychloroquine is same as for group 1 cohort 2.
Visual feedback will be provided to train subjects to attend to a PRL for smooth pursuit eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on a drifting target. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Smooth pursuit tracking behavior will be measured with an eye tracker.
A method is disclosed for producing conjugates, and preferably protein/polysaccharide conjugates. In this process, the polysaccharide is reacted with a reagent so as to provide a functional group on the polysaccharide molecule. Once the functional group is in place, the polysaccharide is reacted with a homobifunctional or heterobifunctional vinylsulfone to produce a vinylsulfone derivatized polysaccharide. Thereafter, the vinylsulfone derivatized polysaccharide is reacted with a protein to produce the conjugate. If desired, the protein may be derivatized with a functional group prior to the conjugation reaction step. In an alternative embodiment, the protein may be functionalized with a reactive group and then derivatized with the vinylsulfone group to produce a vinylsulfone derivatized protein. This protein may then be reacted with a polysaccharide to produce the conjugate. Optionally, the polysaccharide may be functionalized with a reactive group prior to the conjugation reaction. As another alternative, the polysaccharide may be derivatized directly with a pendant vinylsulfone of the cross-linking agent. The vinlysulfone derivatized polysaccharide may then be coupled to the protein (which may or may not be functionalized). In a similar manner, the protein may be derivatized directly with a pendant vinylsulfone of the cross-linking agent and then coupled to a polysaccharide molecule (which may or may not be functionalized).
The invention provides a paroxetine mesylate tablet core, and a preparation method of a coated tablet of paroxetine mesylate. Each paroxetine mesylate tablet core comprises 10 to 40mg of active pharmaceutical ingredient paroxetine mesylate, 20 to 90% of a water insoluble filler, 10 to 60% of a water soluble filler, 3 to 30% of a disintegrating agent, 0 to 10% of an adhesive, and 0.1 to 10% of a flow aid and a lubricant. The paroxetine mesylate tablet core is prepared via wet-method granulation or spray granulation of the ingredients above, and tabletting. The invention also provides the preparation method of the paroxetine mesylate coated tablet. A coating material is opacifying agent-containing opadry or a coating powder composed of 0.5 to 4% of a film forming agent, 0.1 to 2% of a plasticizer, 0.1 to 1% of a colouring agent, 0.1 to 2% of an opacifier, and 0.1 to 1% of a lubricant. The paroxetine mesylate tablet core is subjected to coating using a coating liquid prepared from the coating material. The ingredients of the coating material are commonly used; the preparation method is stable; film coating is capable of covering bitter taste and hemp taste of the main drug, increasing light stability, and improving compliance of patients and stability of preparations. The coated tablet prepared via the preparation method is qualified and stable.
Participants will complete a screening visit to determine study eligibility. During the first week, participants will be asked to abstain from opioid use other than buprenorphine. Participants will come to the clinic 2 times that week for urine drug testing. If all 2 tests are negative, participants will be randomly assigned to take either lofexidine or placebo (inactive medication) two to three times a day for 5 weeks. During this time, participants will upload videos of themselves taking their medication. They will come to the clinic 3 times a week for urine drug screens and to have their vital signs measured. They will also participate in "CREMA" sessions (Cue Reactivity Ecologic Momentary Assessment) 3 times a day. These sessions include looking at stressful and neutral pictures and rating stress and craving. At the end of five weeks, participants will return to the clinic and participate in a stress task and a scripted opioid imagery task the following day. For the next five days, participants will taper their medication dose. During this time they will continue to come to clinic to have their vital signs measured and complete a follow-up visit.
The invention relates to the field of pharmaceutical preparation, in particular to a bilayer osmotic pump controlled-release tablet preparation and a preparation method thereof. Said bilayer osmotic pump controlled-release tablet comprises a conventional tablet core, release control layer(s) and drug release hole(s), wherein one or more lubricating layer structure(s) is/are disposed between the tablet core and the release control layer(s). The lubricating layer(s) is/are present in an amount of from 0.5% to 6% based on the weight of the bilayer tablet core. The lubricating layer(s) rapidly hydrates once in contact with water to form the favorable lubricating liquor between the tablet core and the release control layer(s), hence reducing the shear force between the drug-containing layer(s) and the release control layer(s), whereby the drug-containing layer(s) is/are pushed out completely by the propellant layer(s) to reach a drug release percent of nearly 100%. This solves the problem of the incomplete drug release due to the dead angle generated by the drug-containing layer of a conventional bilayer osmotic pump controlled-release tablet during the release procedure. This technique ensures the superior bioavailability of the bilayer osmotic pump controlled-release tablet as prepared.
A midwife/nurse works with the women according to the following protocol: 1.-identify anal sphincter, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2.- identify elevator ani muscle and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting, bent forward, elbows on knees; 3.- contract elevator ani muscle with a position of sitting, lying, and standing; 4.- contract anal sphincter with a position of sitting, lying, and standing. The sessions are conducted by the same midwife/nurse to women in both groups/arms to be performed by the women at home. .
Behavioral: telerehabilitation activities Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) 5 sessions/week of an individualized telerehabilitation program at home. The sessions will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by the therapist weekly. Each patient's performed session will be reviewed by the therapist.
The invention discloses a culture medium composition for amplifying and maintaining the self-renewal capacity and differentiation potential of Hematopoietic Stem Cells (HSCs), a cell population and application thereof. The medium composition includes a hematopoietic stem cell medium and a small molecule inhibitor of a PDGFR target. Applicants have demonstrated for the first time that inhibitors of PDGFR are able to significantly expand HSCs during in vitro culture while maintaining a high proportion of self-renewal capacity of HSCs. The PDGFR inhibitor found by the applicant has a remarkably better effect of amplifying LT-HSCs than the reported chemical small molecules. This is the first demonstration and report that the PDGF/PDGFR signaling pathway plays an important role in hematopoietic stem cell expansion and maintenance of self-renewal capacity. The research result of the applicant can realize the in vitro amplification of the HSCs and simultaneously maintain the dryness of the cells with higher proportion, and the clinical application of HSCs transplantation can widely treat a series of blood system diseases on the basis.
Patients with Fontan physiology are at increased risk of developing hypotension during periods of illness or with anesthesia. These patients have changes in venous capacitance, compliance, and venomotor tone. When hypotension occurs, the approach to management requires a careful understanding of these changes and the selection of appropriate, efficacious vasoactive agents. Vasoconstrictive medications are frequently used to treat hypotension when patients are refractory to fluid resuscitation. However, most of these medications have an effect on both the systemic and pulmonary circulations, raising the vascular pressures of both circuits. However, these patients often do not tolerate abrupt increases in pulmonary arterial pressures or vascular resistance, and a low transpulmonary gradient is imperative to maintain cardiac output. The ideal agent would be one that raises systemic vascular pressure while having a minimal effect on the pulmonary circulation.

One promising medication for treating hypotension in Fontan patients is vasopressin. One prior study evaluated the hemodynamic effect of vasopressin in pediatric patients with pulmonary hypertension. Compared to other vasopressor agents (phenylephrine, epinephrine), vasopressin increased systemic blood pressure with the least effect on pulmonary artery pressure. In a second study evaluating the use of vasopressin specifically for patients undergoing cardiac surgery for the creation of a Fontan, those who were treated with vasopressin as part of their postoperative management demonstrated lower transpulmonary gradients than those treated with placebo. Other studies have evaluated the use of vasopressin in Fontan patients for other clinical outcomes, such as decreasing postoperative chest tube output. On the basis of these studies, as well as our clinical experience managing these patients in the operating room, procedural suites, and in the intensive care unit, the investigator believes that vasopressin is not only safe but may be the preferred agent for this patient population.

Although vasopressin has been studied extensively in the context of sepsis, post cardiopulmonary bypass, and other vasoplegic disease states, the use of vasopressin has not yet been studied in the general population of patients who have Fontan physiology. The investigator hopes to demonstrate the efficacy of vasopressin as a medication specifically for these patients, as one that can elevate systemic blood pressure without compromising cardiac output or having a deleterious effect on the pulmonary vasculature.
Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to local anesthetic agents or to the methylparaben used as a preservative in the multiple dose vials. Allergic reactions, including anaphylactic reactions, may occur as result of sensitivity to lidocaine, but are infrequent. If allergic reactions do occur, they should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value. 

There have been no reports of cross sensitivity between lidocaine hydrochloride and procainamide or between lidocaine hydrochloride and quinidine.
In addition to usual care: a 1-h educational and training program conducted by the family nurse (FN) in a dedicated room of the ambulatory care centers. During the program, the nurse instructed patients on how to self-measure blood pressure (BP) using the BP self-measurement device and on the importance of adequate device maintenance. The intervention was carried out by the FN on a daily basis during outpatient visits of the participants to the general practitioner (GP).
After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient.
An access control system employing face mask detection and temperature measurement includes a gate access device, a tripod head, a driving module, a camera, a processing device, and a non-touch temperature measuring device. The driving device is configured to drive and thereby move the tripod head. The camera and the non-touch temperature measuring device are disposed on the tripod head. The camera is configured to shoot an image. The processing device is configured to recognize whether a person wears a face mask according to the image, and control the driving module to move the tripod head after recognizing whether an identification object is at a sensing area according to the image. The non-touch temperature measuring device measures a temperature of a temperature sensing portion of the person to generate a temperature signal. When it is determined that the person is wearing a face mask and that the person's temperature meets a standard, the processing device generates an access signal to the gate access device.
Participants participated in a 2-hour Virtual Reality Simulation (VRS), which consisted of 2 simulation scenarios. Participants had to perform nursing assessment and management of virtual patient, followed by communicating with a doctor avatar controlled by the medical student.
Aerosol medicine is widely used in treating pulmonary diseases in children. Delivering drugs via aerosol faces several challenges; some are related to the drug and the delivery methods and others to the patient behavior. The latter are crucial and can significantly affect the lung deposition of the drug. Infants are known to be obligate nose breathers making the transnasal route the natural approach for drug delivery in this age group. Different interfaces are already available in the market and are specifically designed to be used in children to improve the child acceptability of the interface and by the result to improve drug deposition. Due to limitations in the use of radiolabeled aerosols and pharmacokinetics/pharmacodynamics studies in infants and children, in-vitro models were developed. These models still lack biological variability which leads to overestimating lung deposition. So, real life correction factors are needed to improve current in-vitro modeling. Previous unpublished data from our laboratory showed that alignment of the aerosol stream with the nostrils is very important for pulmonary deposition.

Our objectives are to provide real life data of acceptance of different interfaces by infants and children and to provide a real life correction factor to improve current in-vitro modeling.